EIM
SGMO

Essex Investment Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Essex Investment Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-102,223
Closed -$1.73M – 523
2018
Q3 		$1.73M Buy
102,223
+460
+0.5% +$6.99K 0.2% 156
2018
Q2 		$1.45M Buy
+101,763
New +$1.69M 0.18% 172
2015
Q1 		– Sell
-30,684
Closed -$467K – 350
2014
Q4 		$467K Buy
30,684
+7,447
+32% +$90.4K 0.07% 232
2014
Q3 		$251K Buy
+23,237
New +$304K 0.04% 308

Other funds holding SGMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Essex Investment Management's SGMO Position: Q4 2018 in Review

Essex Investment Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2018, closing a stake of 102,223 shares — an estimated $1.73M sold.

Essex Investment Management first reported a position in SGMO in Q3 2014 and held it in 4 quarters. The position peaked at $1.73M in Q3 2018. 197 funds tracked by Wall St. Rank hold SGMO as of Q4 2018.

  • Essex Investment Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2018 after selling out during the quarter.
  • Essex Investment Management sold 102,223 SANGAMO THERAPEUTICS INC shares in Q4 2018, an estimated $1.73M.
  • Essex Investment Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2014 and held it in 4 quarters.
  • Essex Investment Management's SANGAMO THERAPEUTICS INC position peaked at $1.73M in Q3 2018.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2018.

Based on Essex Investment Management's 13F filing for Q4 2018, filed 6 Feb 2019.